Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The Effectiveness of Pharmacist Interventions on Cardiovascular Risk

Open access
Tsuyuki, Ross T., Al Hamarneh, Yazid N., Jones, Charlotte A., Hemmelgarn, Brenda R.·2016·Journal of the American College of Cardiology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2016.03.528

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 29

  1. 2011, Million hearts: strategies to reduce the prevalence of leading cardiovascular disease risk factors–United States, 2011, MMWR Morb Mortal Wkly Rep, 60, 1248
  2. Lim, 2012, A comparative assessment of burden of disease injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010, Lancet, 380, 2224, 10.1016/S0140-6736(12)61766-8 · DOI · Paper page
  3. Braga, 2010, Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada, Can J Cardiol, 26, 297
  4. Al Hamarneh, 2012, Glycemic control in community dwelling patients with type 2 diabetes, Can Pharm J, 145, 68, 10.3821/145.2.cpj68 · doi:10.3821/145.2.cpj68
  5. Ritchey, 2014, Million hearts: prevalence of leading cardiovascular disease risk factors–United States, 2005-2012, MMWR Morb Mortal Wkly Rep, 63, 462
  6. Leiter, 2013, Type 2 diabetes mellitus management in Canada: is it improving?, Can J Diabetes, 37, 82, 10.1016/j.jcjd.2013.02.055 · DOI
  7. Grover, 2011, The challenges and benefits of cardiovascular risk assessment in clinical practice, Can J Cardiol, 27, 481
  8. Shiu, 2006, Quantifying opportunities to affect diabetes management in the community, Can Pharm J, 139, 37
  9. Vivian, 2001, Improving blood pressure control in a pharmacist-managed hypertension clinic, Pharmacotherapy, 21, 1337, 10.1592/phco.21.17.1337.34424 · DOI
  10. Scott, 2006, Outcomes of pharmacist-managed diabetes care services in a community health centre, Am J Health-Syst Pharm, 63, 2116, 10.2146/ajhp060040 · DOI
  11. Santschi, 2011, Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials, Arch Intern Med, 171, 1441, 10.1001/archinternmed.2011.399 · DOI · Paper page
  12. Tsuyuki, 2002, A randomized trial of the effect of community pharmacist intervention on cholesterol risk management – the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP), Arch Intern Med, 162, 1149, 10.1001/archinte.162.10.1149 · DOI · Paper page
  13. McLean, 2008, A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus – Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN), Arch Intern Med, 168, 2355, 10.1001/archinte.168.21.2355 · DOI · Paper page
  14. Kassamali, 2011, Case finding: the missing link in chronic disease management, Can Pharm J, 144, 170, 10.3821/1913-701X-144.4.170 · doi:10.3821/1913-701x-144.4.170
  15. Daskalopoulou, 2015, The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension, Can J Cardiol, 31, 549
  16. Wilson, 2012, An international model to predict recurrent cardiovascular disease, Am J Med, 125, 695, 10.1016/j.amjmed.2012.01.014 · DOI · Paper page
  17. Grover, 2007, Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy. The CHECK-UP Study: a randomized controlled trial, Arch Intern Med, 167, 2296, 10.1001/archinte.167.21.2296 · DOI · Paper page
  18. 2013, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney Int Suppl, 3, 1
  19. 2013, Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada, Can J Diabetes, 37, S1
  20. Hackam, 2013, The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension, Can J Cardiol, 29, 528
  21. Genest, 2009, 2009 Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult–2009 recommendations, Can J Cardiol, 25, 567
  22. Anderson, 2013, 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult, Can J Cardiol, 29, 151
  23. Tobe, 2011, Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE initiative, CMAJ, 183, E1135, 10.1503/cmaj.101508 · DOI
  24. Al Hamarneh, 2013, Pharmacist intervention for glycaemic control in the community (the RxING study), BMJ Open, 3, 10.1136/bmjopen-2013-003154 · DOI
  25. Tsuyuki, 2015, Randomized trial of the effect of pharmacist prescribing on improving blood pressure in the community: the Alberta clinical trial in optimizing hypertension (RxACTION), Circulation, 132, 93, 10.1161/CIRCULATIONAHA.115.015464 · DOI · Paper page
  26. O’Donovan, 2014, Pharmacist’s use of screening tools to estimate risk of CVD: a review of the literature, Pharmacy, 2, 27, 10.3390/pharmacy2010027 · DOI
  27. McNamara, 2010, Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the pharmacist assessment of adherence, risk and treatment of cardiovascular disease (PAART CVD) pilot study, BMC Health Serv Res, 10, 264, 10.1186/1472-6963-10-264 · DOI
  28. Al Hamarneh, 2016, Community pharmacists targeted screening for chronic kidney disease, Can Pharm J, 149, 13, 10.1177/1715163515618421 · doi:10.1177/1715163515618421
  29. Curtis, 2015, Online clinical pathway for managing adults with chronic kidney disease, Can Pharm J, 148, 257, 10.1177/1715163515597243 · DOI

Cited by

See all 209

Metadata

Authors
Tsuyuki, R. T., Al Hamarneh, Y. N., Jones, C. A., & Hemmelgarn, B. R.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2016-06
Volume
67
Issue
24
Pages
2846-2854
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2469548291
Cited by
209
References
6
FWCI
26.66
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effectiveness of Pharmacist Interventions on Cardiovascular Risk. https://app.cochat.ai/papers/10.1016/j.jacc.2016.03.528
The paper
Tsuyuki, R. T., Al Hamarneh, Y. N., Jones, C. A., & Hemmelgarn, B. R. (2016). The Effectiveness of Pharmacist Interventions on Cardiovascular Risk. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2016.03.528

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.